论文部分内容阅读
目的分析溃疡性结肠炎(UC)活动期的临床疗效及治疗转归,评价预后相关因素。方法回顾性分析216例住院患者的病例资料,记录临床表现及诊疗经过,对柳氮磺吡啶(SASP)或5-氨基水杨酸(5-ASA)、糖皮质激素、免疫抑制剂、灌肠、外科手术等治疗方法的疗效进行评价。结果活动期UC患者中,轻度占25.0%(54/216),中度占50.9%(110/216),重度占24.1%(52/216);SASP或5-ASA是控制症状的主要药物,对于中度UC患者,联合用药治疗效果较为理想。而发病年龄轻、结肠病变范围大、低血红蛋白、大便以血为主、低血清白蛋白、病变伴有溃疡是提示疗效差的相关因素。结论对于UC病变处于活动期时,应及时评估病情严重程度,选择疗效相对较好的治疗方案,并分析影响疗效相关因素。
Objective To analyze the clinical efficacy and prognosis of ulcerative colitis (UC) during the active phase and evaluate the prognostic factors. Methods A retrospective analysis of 216 cases of hospitalized patients with clinical data and records of clinical experience after treatment of sulfasalazine (SASP) or 5-aminosalicylic acid (5-ASA), glucocorticoids, immunosuppressive agents, enema, Surgery and other treatment methods to evaluate the efficacy. Results In active UC patients, mild (25%) (54/216), moderate (50/210%) and severe (24.1%) patients (52/216), SASP or 5-ASA were the main drugs for symptom control , For patients with moderate UC, combined treatment is more satisfactory. The incidence of age, colonic lesions range, low hemoglobin, stool to blood-based, low serum albumin, lesions associated with ulcers are associated with poor efficacy. Conclusion In the active stage of UC lesions, the severity of the disease should be assessed in time, the treatment options with relatively good curative effect should be selected, and the factors influencing curative effect should be analyzed.